4//SEC Filing
Flynn Daniel Lee 4
Accession 0001209191-21-070227
CIK 0001654151other
Filed
Dec 16, 7:00 PM ET
Accepted
Dec 17, 4:00 PM ET
Size
9.3 KB
Accession
0001209191-21-070227
Insider Transaction Report
Form 4
Flynn Daniel Lee
Chief Scientific Officer
Transactions
- Award
Common Stock
2021-12-15+11,100→ 28,732 total - Award
Stock Option (Right to Buy)
2021-12-15+82,265→ 82,265 totalExercise: $9.23Exp: 2031-12-14→ Common Stock (82,265 underlying)
Holdings
- 230,435(indirect: By Trust)
Common Stock
- 91,020(indirect: By Trust)
Common Stock
Footnotes (2)
- [F1]The reporting person was awarded 11,100 Restricted Stock Units ("RSUs") under the Issuer's 2017 Stock Option and Incentive Plan (the "2017 Plan"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in two equal installments on June 15, 2022 and June 15, 2023, subject to continuous service with the Issuer or a Subsidiary (as defined in the 2017 Plan) through such dates. The RSUs may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
- [F2]This stock option was issued pursuant to the 2017 Plan. The option shall vest in two equal installments on June 15, 2022 and June 15, 2023, subject to continuous service with the Issuer or a Subsidiary (as defined in the 2017 Plan) through each vesting date.
Documents
Issuer
Deciphera Pharmaceuticals, Inc.
CIK 0001654151
Entity typeother
Related Parties
1- filerCIK 0001713712
Filing Metadata
- Form type
- 4
- Filed
- Dec 16, 7:00 PM ET
- Accepted
- Dec 17, 4:00 PM ET
- Size
- 9.3 KB